1350619-77-0

Basic information

• Product Name: Grazoprevir interMediate
• Synonyms: Grazoprevir interMediate;(1R,2R)-2-(4-Pentyn-1-yl)cyclopropanol;Cyclopropanol, 2-(4-pentyn-1-yl)-, (1R,2R)-;(1R,2R)-2-(pent-4-yn-1-yl)cyclopropan-1-ol;EOS-61021
• CAS NO: 1350619-77-0
• Molecular Formula: C8H12O
• Molecular Weight: 124.18028
• EINECS: -0
• Product Categories: intermediates
• Mol File: 1350619-77-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 186.3±13.0 °C(Predicted)
• Appearance: /
• Density: 1.025±0.06 g/cm3(Predicted)
• PKA: 15.26±0.40(Predicted)
• CAS DataBase Reference: Grazoprevir interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: Grazoprevir interMediate(1350619-77-0)
• EPA Substance Registry System: Grazoprevir interMediate(1350619-77-0)

Safety Data

• Hazardous Substances Data: 1350619-77-0(Hazardous Substances Data)

Usage

General Description

"Grazoprevir intermediate" is a chemical used in the synthesis of grazoprevir, which is a medication used to treat chronic hepatitis C virus (HCV) infection. The intermediate is an important component in the manufacturing process of grazoprevir and is used to form the structural backbone of the active pharmaceutical ingredient. It is a key building block in the production of grazoprevir and plays a crucial role in the creation of the final medication. The intermediate undergoes various chemical reactions and processes to ultimately produce the final compound, which is then formulated into a medication for use in treating HCV infection.

Upstream product

• 1224174-07-5 (S)-1-chlorohept-6-en-2-ol 
• 154820-95-8 2-(5-chloropent-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 136835-38-6 (E)-2-(3-chloropropyl)-1-cyclopropanol 
• 126726-63-4 2-[2-(3-chloropropyl)cyclopropyl]-4,4,5,5-tetramethyl[1,3,2]dioxaborolane 

Downstream Products

• 1206524-84-6 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1206524-85-7 (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradeca-hydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid hydrate 
• 1449296-59-6 C₁₇H₂₂O₃ 
• 1425038-19-2 (S)-3,3-dimethyl-2-(((1R,2R)-2-(pent-4-ynyl)cyclopropoxy)carbonylamino)butanoic acid 
• 1425038-21-6 (S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid tert-butylamine salt 
• 1425038-23-8 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-18,19-didehydro-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3, 6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1350514-68-9 grazoprevir 
• 1534367-63-9 C₃₂H₄₁N₃O₇ 
• 1534367-62-8 C₃₉H₄₃N₃O₇ 
• 1534367-61-7 (S)-2-((((1R,2R)-2-(5-(4-(benzyloxy)-2-(((3R,5S)-1-(tert-butoxycarbonyl)-5-(methoxycarbonyl)pyrrolidin-3-yl)oxy)quinolin-3-yl)pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)-2-cyclohexylacetic acid 
• 1613315-35-7 C₃₁H₃₉N₃O₇ 

Relevant articles and documents

Asymmetric Synthesis of Functionalized trans-Cyclopropoxy Building Block for Grazoprevir

A practical and asymmetric synthesis of a functionalized trans-cyclopropoxy building block for the preparation of the HCV NS3/4a protease inhibitor grazoprevir is reported. Intramolecular SN2 displacement-ring closure, followed by a Baeyer-Villiger oxidation, yields the desired trans-cyclopropanol with full control of diastereoselectivity. A terminal alkyne is then effectively installed using LiNH(CH2)2NEt2. Starting from (S)-epichlorohydrin, the cyclopropoxy building block is prepared in 51% overall yield with >99.8% optical purity without isolation of any intermediates.

METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS

The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.

CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR

The present invention relates to different forms of a HCV inhibitory compound.